Agios Pharmaceuticals
AGIO
152 hedge funds and large institutions have $1.68B invested in Agios Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 63 increasing their positions, 50 reducing their positions, and 22 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 50
24% more capital invested
Capital invested by funds: $1.36B → $1.68B (+$325M)
0.36% more ownership
Funds ownership: 106.45% → 106.81% (+0.36%)
7% less funds holding
Funds holding: 163 → 152 (-11)
45% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 22
56% less call options, than puts
Call options by funds: $5.2M | Put options by funds: $11.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$32.2M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$14.8M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$8.04M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$4.64M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$4.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$12M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$11.7M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.11M |
| 4 |
AC
Armistice Capital
New York
|
-$5.08M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$4.89M |
AGIO Hedge Fund Activity: Q2 2023 in Review
152 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2023, worth a combined $1.68B — up 24% from $1.36B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AGIO and 12 opened new positions — a net loss of 10 holders — while 50 trimmed existing stakes and 63 added.
The largest buyer was JP Morgan Chase, adding an estimated $32.2M. The largest seller was State Street, cutting an estimated $12M.
- 152 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2023, down from 163 in Q1 2023.
- Funds reported $1.68B of Agios Pharmaceuticals stock for Q2 2023, up 24% quarter-over-quarter.
- 12 funds opened new Agios Pharmaceuticals positions in Q2 2023 and 22 closed out, a net change of -10 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2023 was JP Morgan Chase, an estimated $32.2M added.
- The largest Agios Pharmaceuticals seller in Q2 2023 was State Street, an estimated $12M sold.
Based on aggregated 13F filings for Q2 2023.